Biopharma Co. Sues Over Cancer Drug Clinical Trial Mix-Up

By Daniel Wilson (September 26, 2012, 2:40 PM EDT) -- Peregrine Pharmaceuticals Inc. on Monday sued a clinical testing company in California federal court, alleging it mixed up the results of a clinical trial for a new cancer treatment, causing Peregrine to have to rescind its promising trial results.

According to the Tustin, Calif.-based biopharmaceutical company's complaint, Fargo, N.D.-based Clinical Supplies Management Inc. ran one of three randomized, double-blind, placebo-controlled Phase II trials for the drug bavituximab as part of a testing services agreement with Peregrine. Bavituximab, a first-of-its-kind monoclonal antibody treatment that prompts the immune system to attack cancer and virus cells, was being tested for treatment of non-small cell lung...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!